December 26, 2014 12:26 AM ET

Pharmaceuticals

Company Overview of Aduro BioTech, Inc.

Company Overview

Aduro BioTech, Inc., a clinical-stage biotechnology company, develops immunotherapy solutions for the treatment of cancer. The company develops a pipeline of new immunotherapies and immunotherapy combinations, including CRS-207, a solution based on Listeria platform to express the tumor-associated antigen mesothelin in patients with metastatic pancreatic cancer; and ADU-623, a clinical bivalent Listeria-based immunotherapy for patients with glioblastoma. It also develops ADU-214, a bivalent Listeria-based immunotherapy that targets mesothelin and EGFR mutations; ADU-741, a solution based on live-attenuated double-deleted immunotherapy platform for the treatment of prostate cancer; cyclic din...

626 Bancroft Way

Suite 3C

Berkeley, CA 94710-2224

United States

Founded in 2000

Phone:

510-848-4400

Fax:

510-848-5614

Key Executives for Aduro BioTech, Inc.

Chairman
Age: 65
Vice President of Finance
Age: 41
Chief Operating Officer
Age: 50
Senior Vice President of Research & Development
Head of Molecular Biology
Compensation as of Fiscal Year 2014.

Aduro BioTech, Inc. Key Developments

Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies

Aduro BioTech, Inc. announced that it has entered into its second agreement with Janssen Biotech, Inc., granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization. Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities. The transaction is subject to clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become final as soon as such clearance has occurred.

Aduro BioTech, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

Aduro BioTech, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

Aduro BioTech, Inc. Presents at BIO-Europe 2014, Nov-03-2014

Aduro BioTech, Inc. Presents at BIO-Europe 2014, Nov-03-2014 . Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Similar Private Companies By Industry

Company Name Region
Pharmline Inc. United States
Drugs Unlimited, Inc. United States
Norian Corporation United States
Blend Therapeutics, Inc. United States
Daiichi Sankyo, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 16, 2014
Aduro BioTech, Inc., Worldwide License Based on Novel LADD Immunotherapy Platform
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aduro BioTech, Inc., please visit www.aduro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.